Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't know enough about Sabby. I might be way off base but I don't think management would take money from anyone they thought would hurt them.
No idea on Schneider. I don't know if no news means they're working on another raise or they have to be silent while they finalize the deal. I don't think anyone is panicking.
Tell me what You think about Sabby and if it makes It harder to attract investors....
Hear anything about Schneider....clock is ticking
It's insane that the states have been allowed to let it go this far with no Federal scrutiny. There is no other drug I can think of that has been given this kind of leeway. There are no studies to support the benefits of what's being sold and no studies on the risks and side effects. It's complete lawlessness and we all know the majority is for recreational purposes.
This might be the first chip at the stone but once Pharma has drugs to protect, there's going to be a war. If the drugs are effective, I dont see how medical marijuana survives. Pharma will be much cheaper, safer and doctors will only prescribe approved drugs. It will be a tough fight becasue so much money and infrastructure has been poured into mm but they won't have a leg to stand on if there are effective FDA approved drugs.
Vinpat said this would happen
https://www.marijuanamoment.net/fda-review-medical-claims-marijuana/
I hope you Know the jockey you picked because the Race is about to start
THIS IS NOT A DRILL
i wrote that for my friend Vinpat a Long time ago
Reminder when calculating EV and market cap
There are still preferred shares from the Series B and D financings that could be converted and should be considered when doing calculations
4.5m ---> Series B
3.8m --> Series D
11.7m --> Warrants
30.5m ---> s/o current
Total possible Shares outstanding = around 50 million
Sabby Capital is not a Joke and people should tread lightly
Joshua Berkowitz has over 3 million warrants and used to be a Soros protege....
Some very heavy hitters involved here, be careful
GLTFA
Older article long,but interesting! JULY 28,2017-------------------https://theroadufollowed.wordpress.com/2017/07/28/therapeutic-effects-of-cannabis-and-nemus-bioscience/ (Nemus Bio-science)Part; Nemus develops totally synthetic cannabinoid molecules for therapeutic purposes. The company entered into a memorandum of understanding (MOU) with the University of Mississippi School of Pharmacy (UM) in 2013. The MOU outlines how Nemus and the UM will develop and commercialize cannabinoid therapeutics. Up until recently, the UM was the only entity permitted to cultivate cannabis for research purposes in the USA. This federal license was first issued in 1968. Nemus went public through a reverse takeover (RTO) in 2014 and is traded on the OTCQB (Symbol: NMUS). They have a fully diluted market cap of 15 million USD and will need to raise significant capital in the future. Since 2013, Nemus and the UM have entered into four exclusive option agreements for two cannabinoid compounds developed by the school. One of the compounds is a THC pro-drug; NB1111 is eye drops for glaucoma and NB1222 is a suppository for chemo-induced nausea and vomiting (CINV). The other is a analogue version of CBD; NB2111 for CIPN and NB2222 for different ocular targets. Nemus and the UM are working together to develop a composite of cannabinoids to fight methicillin-resistant Staphylococcus aureus (NB3111).
The UM first started publishing data comparing THC suppository formulations and Dronabinol in 1991. NB1222 has improved bioavailability since it bypasses the first past effect. When compared to Dronabinol, NB1222 has a longer therapeutic window and more stable dosing. Depending on the patient’s condition, suppositories can be a valuable delivery system. Nemus believes their suppository can efficiently deliver the API in a once per day dose. NB1222 avoids the upper gastrointestinal tract, which helps reduce nausea and vomiting. Nemus claims they will file a NDA for their suppository through the 505(b)(2) expedited FDA pathway in the future. Nemus will have to raise additional funds to show the effectiveness of NB1222 in clinical trials.
As glaucoma develops, intraocular pressure (IOP) is a risk factor that can cause eye damage. There is a large concentration of cannabinoid receptors in the eye. THC has shown to lower IOP in studies involving humans and animals. Furthermore, THC has neuroprotective qualities including disrupting deterioration of the optic nerve. While smoking cannabis lowers IOP, it has a small half-life and reduces blood flow to the eye. The UM began researching THC effects on IOP in the 1980’s. Nemus and the UM recently presented research showing NB1111 reducing IOP levels in rabbits similar to other glaucoma drugs with significant market share. The concentration of THC in the formulation was around one percent. The drops are absorbed in different parts of the eye, reducing systemic exposure and bypassing the first past effect. The rabbit ocular model is acceptable for regulators considering candidates for human testing. UM & Nemus have protected NB1111 with patents on the API and delivery system awarded in USA, Japan, UK and Hong Kong. Nemus will have to raise additional funds to show the effectiveness of NB1111 in clinical trials. The glaucoma market is hyper-competitive.
Abuse of opioids is a serious problem; Nemus intends to develop CBD derivatives for multiple types of pain syndromes in the future. Research conducted by Nemus and the UM has shown different composites of cannabinoids having synergistic bactericidal activity. All of the candidates will bypass the first past effect. The pathway to commercialization for the CBD analogue’s and NB3111 would be significantly more difficult than Nemus’s THC prodrugs. Pain relief metrics can be ambiguous and there are non-cannabinoid MRSA treatments that show promise. The ability to raise funds and continue their research into these indications will determine if they are viable therapeutics.
For Nemus to realize the potential of their pipeline, the company has to raise additional capital. When a company’s potential growth is based upon raising funds through issuing equity, individuals usually do not apply appropriate risk when modeling that company’s value. In the past, Nemus has raised capital by issuing equity and this is likely to happen again. This would be dilutive for existing shareholders. Nemus has never generated revenues and is unlikely to for the foreseeable future. Nemus went public through a RTO; the SEC has warned significant risks are involved investing in a company that has gone through a RTO. Individuals from the former company (Lock Guard Logistics) that received common stock as a result of the RTO have liquidated the majority of their holdings. The 1 year return on Nemus common stock is approximately -50%. Nemus has 11.5 million warrants outstanding with an average strike price of $0.40 USD. Nemus trades on a small exchange and has poor liquidity. Historical guidance from the company targeted 2017 for IND filings and commencement of clinical trials. Nemus has not filed an IND to date and is unlikely to begin clinical trials in 2017. Legal proceedings were brought against Nemus by their former CEO John Hollister in 2015. The claims and counter claims were withdrawn in 2016 by both parties; John Hollister submitted a statement expressing regret for beginning the proceedings. No payments were made by either party to resolve the matter.
The author believes total synthetics should be the standard when utilizing the cannabis plants therapeutic effects. They have better safety and economics when compared to plant-derived peers. Furthermore, cannabis flower, oil, gel caps and other edibles for medical use should be considered substandard. Nemus Bioscience has the most sagacious drug pipeline in cannabinoid drug development. The UM possess intellectual property superior to any cannabinoid drug developer. Nemus has chosen to advance candidates with objective measures and established safety profiles to reduce development costs. Historically, the company has been able to raise sufficient capital for their day-to-day operations, research and drug development. In addition, prior equity raises have been completed diligently. If this continues, it’s possible Nemus will advance NB1111 and NB1222 into clinical trials during 2018.
Sabby Capital has had Puts worth 4.5m for $GWPH since Q1 2015
They didn't own any GW in Q1 2017 and bought 1.5m position in Q2 2017
This Is not a Drill and you should know what you Own
Because more people are buying than selling
No
Sabby Capital is run by Hal Mintz. Apparently, it had over 2b in AUM and its two funds specialize in biotech/pharma. It looks like they have around 900m AUM currently
I've read different things that are mostly good. I have looked for awhile for bad things, but only a Few tweets about them 'manipulating the SP' and harmful financing for small caps.
is sabbby connected with schnieder...?
What is everyone thoughts on Sabby Capital?
Who own 40% of s/o
They seem to be Big time, although their AUM has been cut in half last few years
Starting to think it is Sabby, and not MM, having fun with the SP
It was exercised a few days after they missed the deadline for payment
It is the SEC filings somewhere
Which says to me 'were working with them' is a kind way of putting it. Nemus does not have the $ to sue though..
So since the company hasn't released anything the last while, were stuck in a uncertain time and I guess the SP reflects that
Last three months of the year Should be a wild ride
Does anyone know if Nemus actually exercised the $20 million guaranty yet? I admit I haven't been able to follow this as closely as I would like the last few months, so I easily could have missed it. However, the last I saw was: "The Company intends to continue to work with Schneider Finance to close the transaction either directly with Schneider Finance LLC and their affiliates or through the exercise of the $20 million guaranty that provides for payment of the purchase price in full within 90 days of exercise."
Was the guaranty exercised? Or are they still working with Schneider Finance LLC to close the deal? I guess I assumed that they exercised it right away on July 11, but now I'm not so sure. Any insight from you guys would be greatly appreciated. Thanks
Fully diluted and including Series E financing
What are you basing this on? TDAmeritrade has today's prices at a 7.4 million market cap. Are they wrong, because that would only be around a 122 million market cap at 4.00
Who wanted out?
I want progress. Ill be in until Murphy is in his grave.
Citadel has a 173k bid at .273
Lots of liquidity if you want out
Not letting go of this one easily
Clicking my heels 3 times today for the close of financing and announcement of IND in October.
Long .25 to .32 if it can hold above .32 and trend up then ill stay with the houses money. Todays sell off in the am with buys in the Pm is a good sign. News should drop around oct 1st.
What short term pop do you have in mind?
short term pop in play, hope you collected 24-25s were going up for a short term, dont count on it to stick, they usually release news when the graph looks like this.
anton jerkin has at least lost 2-3K in this stock guaranteed, bag holding cheerleaders like his girlfriend vinpat dont write consistently on a board they arent heavily emotionally invested in.
toodle looo
My manufacturing? What are you talking about?
Murphy said they would aggressively look at uplisting with the $20mm raise, which would necessitate a reverse split. Not sure why you're arguing.
'Valeant acquired Cesamet from Eli Lilly in 2004 and already sells the product in Canada, where it has about an 86% share of the cannabinoid market, accoridng to IMS data. It expects to launch Cesamet in the USA within the next few weeks.'
'Nabilone was originally developed by Eli Lilly and Company; Lilly received FDA approval in 1985 to market it, but withdrew that approval in 1989 for commercial reasons.[9] Valeant Pharmaceuticals acquired the rights from Lilly in 2004.[9] Valeant tried and failed to get the drug approved in 2005[10] and then succeeded in 2006.[9]'
Murphy CSO at VRX 2003-2006
DYODD
$4 a share would be a 440m market cap
420m EV
With a fully funded Phase 1 trial of NB1222/NB1111 and then positive results, we would be Off to the races. Look at $ZYNE at its Peak , much higher
And Look at GW. SPent a Lot of time on their first drug that WILL NEVER get approved in the USA as a medicine. Maybe one day as a rec product. And now a new Drug in Phase 3 trials, when asked about the science of your manufacturing you give toss a word salad and conclude with 'sorry about unscientific answer', and now doubt about whether the benefit of CBD is directly from the molecule or an interaction with other epilepsy drugs.
Still 1B market cap.
I have them Right between the eyes, whether they know it or not
And I hope $ZYNE goes higher but some People are probably pretty mad at Management
I'm not short either and wish them Good luck
The financing would add 67mm shares.
If the right news comes out with the financing and phase 2 trials the price could go to 4.00+ on its own with their very low share structure.
You sound like a noob. They want to uplist if the $20mm closes, so they would have to reverse split to get to $4/share.
Dilution is one of the biggest risks in investing in microcaps, so it's important they raise what they need.
chicos back fellas, lets pop .32 and run her down past .24, Collecting shares throughout October for the holidays.
And the reverse Split is Fake news
They do not need to do one; to many potential catalysts that would take this SP to a level where they could uplist
They are a small cap biotech
No such thing as not enough money.
I doubt they have just been twiddling their thumbs for the last few months.
Will be an interesting end to the year to see where this goes in 2018
I think you're right, Anton. Schneider only has a couple weeks to close, and I'm not that confident it will happen. That is completely fine with me. It sounds like Nemus went for more than they really needed so they could reverse split and uplist. I don't like the OTC either, but they should focus on the pipeline. They need to just raise a few million and get things going.
if your answer to a question about the science involved in your product
involves 'why change something that we already believe works and works well' and 'Perhaps an unscientific answer'
You might want to rethink what you are Doing
DYODD
kinda dramatic
you bought the ticket, take the ride
If you need something to cheer you up, go read the conference call of Gover at MorganStanley conference
' So it’s more a question of why change something that we already believe works and works well.'
https://seekingalpha.com/article/4106691-gw-pharmaceuticals-gwph-ceo-justin-gover-presents-morgan-stanley-global-healthcare-conference?page=7
That attitude will work out Very well for them. "If you don't like change, you'll like irrelevancy worse."
Fully diluted, were nearing the EV of ZYNE
Matter of time before we Take the top spot
Day to day is just a mark
GLTFA
This is excruciatingly painful.
At some point theyve got to invest in getting their name out there. IMLFF's pumps are just a representation of the market in 2017. If you dont invest capital in promotion then you let the crooks have complete control to decimate the SP, which in turn decimates the company. And the crooks will NEVER LOSE.
Frustrating.
Not sure but I've heard he's difficult to deal with. I believe a google search may bear that out.
I really don't like it either. Bogart and Schneider are getting to Eric A I think...
What happened with Dr. Weinreb, vinpat? Hope you are well
I doubt it had much impact on the PPS. It was trading in the 40's before the pump hit and I think the price would have dropped to where it is now pump or no pump. I doubt Nemus even knows about this unless the SEC notified them and clearly they had no part in it. Another example why penny stocks are dangerous and you should only buy if you know the players or and if they have a good track record. It's also another reason why Nemus is but the book.
It's why I question what InMed is doing when paying for the pumps. It makes me nervous becasue legit companies don't do it. I see the argument a couple posters make for it but it's sleazy.
Vinpat, how much damage did those traders do?
Has it been a headache dealing with that crap?
The guys who did it are getting sued by the SEC
https://www.sec.gov/litigation/complaints/2017/comp-pr2017-124.pdf
Nemus is named in the complaint, but is not listed as a part of the scam.
Very annoying. I had to go through all the defendants names in old SEC filings for Lock Guard and all the guys who were sold securities (no match).
Let us know if you find anything out, first hand. I've heard they aren't good at answering important questions (nothing material, of course) - at least by email. I'd love to attend a conference or presentation, as you know I have a number of questions.
If it falls through I'm sure they have a contingency. They were smart enough to promptly exercise the guaranty. Schneider has been wasting a lot of time.
28 days
Until Schneider needs to pay
No PR since Aug 7
I would think some sort of
Financial deals are occuring
What's going on with this. Any updates?
just to be clear
I think Nemus has a monopoly when thinking about cannabinoid drug development. They stop doing pumps a Long time ago and they possess is the Real deal
It takes Courage but I like the jockeys and will get all my questions answered,.
Followers
|
138
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6315
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |